Lupin has announced that its subsidiary, Lupin Pharmaceuticals Inc has launched Suprax 400 mg tablets (Cefixime USP) in the US. This line extension, further extends the brand franchise of Lupins flagship anti-intective Suprax.
Suprax 400 mg tablets will help Lupin to further increase its share of the $450 million antibiotic market for the treatment of urinary tract infections. It will also extend the use of Suprax to the patient population of children of the age of 12 yrs and above.
Suprax 400 mg tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors- Its efforts will he supplemented by innovative promotional campaigns.
The Suprax brand basket now includes, Suprax (Cefixime for oral suspension 100 mg / 5 ml and 200 mg / 5ml and Suprax 400 mg tablets (Cefixime USP).
More...




0 comments ↓